Prognostic Value of Neutrophil-Related Factors in Locally Advanced Cervical Squamous Cell Carcinoma Patients Treated with Cisplatin-Based Concurrent Chemoradiotherapy

Table 7

The summary of NLR studies in cervical cancer.

Patient; number	Median age; (range, years)	FIGO stage	Histology	Treatment	Median NLR/cut-off; value of NLR	Association of NLR with; clinicopathologic characteristics	Prognostic factor determined; in multivariable analysis	Reference
1061	50 (21–85)	IB1-IVA	SCC, AC, ASC	Surgery + RT or CRT	1.9/1.9	Age, stage, treatment modality	NLR	[9]
111	42 (21–68)	IB2-IIB	SCC, non-SCC	NCT + surgery	2.4/2.5	FIGO stage	LN metastasis, lymphovascular space involvement	[10]
460	44 (24–78)	I-II	SCC, AC	Surgery + RT	2.213/2.213	Depth of stromal infiltration, LN metastasis	NLR, FIGO stage and LN metastasis	[11]
56	65.1 (35–89)	IB1-IV	SCC	RT or CRT	2.4/2.5	FIGO stage, mean SCC value, tumor size, LN metastasis, CR	NLR	[12]
60	53 (36–80)	II-III	SCC	CRT	2.4/2.0	Age, baseline platelet count	NLR	Current study

NLR, neutrophil-lymphocyte ratio; FIGO, International Federation of Gynecology and Obstetrics; SCC, squamous cell carcinoma; AC, adenocarcinoma; ASC, adenosquamous cell carcinoma; RT, radiotherapy; CRT, chemoradiotherapy; NCT, neoadjuvant chemotherapy; LN, lymph node; CR, complete response.